Literature DB >> 22687521

A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers.

Rafael Mariano de Bitencourt1, Fabrício Alano Pamplona, Reinaldo Naoto Takahashi.   

Abstract

Emotional learning is extremely important for the survival of an individual. However, once acquired, emotional associations are not always expressed. The regulation of emotional responses under different environmental conditions is essential for mental health. Indeed, pathologic feelings of fear and anxiety are defining features of many serious psychiatric illness, including post-traumatic stress disorder (PTSD) and specific phobias. The simplest form of regulation of emotional responses is extinction, in which the conditioned response to a stimulus decreases when reinforcement (stimulus) is omitted. In addition to modulating basal anxiety states, recent studies suggest an important role for the endocannabinoid (eCB) and glucocorticoid systems in the modulation of emotional states and extinction of aversive memories in animals. The purpose of this review is to briefly outline the animal models of fear extinction and to describe how these have been used to examine the potential of extinction enhancing agents which specifically alter the eCB and glucocorticoid systems. Pharmacological manipulations of these systems by agents such as cannabinoid or glucocorticoid agonists can enhance the extinction process and avoid the retention of memories which have the potential to trigger trauma. A better understanding of these findings through animal models highlights the possibilities of using combined extinction enhancing agents in exposure-based psychotherapies for anxiety disorders related to inappropriate retention of aversive memories. This article is part of a special issue entitled 'Cognitive Enhancers'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687521     DOI: 10.1016/j.neuropharm.2012.05.039

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  20 in total

Review 1.  Stress, glucocorticoids and memory: implications for treating fear-related disorders.

Authors:  Dominique de Quervain; Lars Schwabe; Benno Roozendaal
Journal:  Nat Rev Neurosci       Date:  2016-11-24       Impact factor: 34.870

2.  2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons.

Authors:  Alvaro Llorente-Berzal; Ana Luisa B Terzian; Vincenzo di Marzo; Vincenzo Micale; Maria Paz Viveros; Carsten T Wotjak
Journal:  Psychopharmacology (Berl)       Date:  2015-03-28       Impact factor: 4.530

Review 3.  Animal models of fear relapse.

Authors:  Travis D Goode; Stephen Maren
Journal:  ILAR J       Date:  2014

Review 4.  Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research.

Authors:  Santiago Papini; Gregory M Sullivan; Denise A Hien; Erel Shvil; Yuval Neria
Journal:  Biol Psychol       Date:  2014-11-04       Impact factor: 3.251

Review 5.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

Review 6.  Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.

Authors:  Matthew N Hill; Patrizia Campolongo; Rachel Yehuda; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2017-07-26       Impact factor: 7.853

Review 7.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

8.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

9.  Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis.

Authors:  Caitlin E Carey; Arpana Agrawal; Bo Zhang; Emily D Conley; Louisa Degenhardt; Andrew C Heath; Daofeng Li; Michael T Lynskey; Nicholas G Martin; Grant W Montgomery; Ting Wang; Laura J Bierut; Ahmad R Hariri; Elliot C Nelson; Ryan Bogdan
Journal:  J Abnorm Psychol       Date:  2015-11

10.  Cannabinoids prevent the effects of a footshock followed by situational reminders on emotional processing.

Authors:  Nachshon Korem; Irit Akirav
Journal:  Neuropsychopharmacology       Date:  2014-06-05       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.